- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07554157
Development of a Pan-Cancer Screening Model Based on Blood Biomarkers (PanCanBlood)
Establishment of a Pan-Cancer Screening Model Based on Blood Biomarkers
Study Overview
Detailed Description
Background: Cancer is a leading cause of death worldwide. Early detection improves survival, but current screening methods (e.g., endoscopy, imaging) are invasive, costly, or not widely accessible. Blood-based biomarkers offer a non-invasive, repeatable, and cost-effective alternative.
Objective: Primary: To establish a pan-cancer screening model based on blood biomarkers. Secondary: To combine multiple blood markers for identifying high-risk populations. Exploratory: To develop a cost-effective, scalable screening technology.
Study Design: This is a multicenter, retrospective study. Data will be collected from 15 participating hospitals in China, including Zhejiang Cancer Hospital, Tongling People's Hospital, Pingyang People's Hospital, Fenghua People's Hospital, Shaoxing Central Hospital, Bingqi General Hospital, the Second Affiliated Hospital of Jiaxing University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Yunnan Cancer Hospital, Xianju People's Hospital, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, No.9 Hospital Ningbo, Norinco General Hospital, Quzhou Kecheng People's Hospital.
Participants: Approximately 10,000,000 patients aged 18-80 years with pathologically confirmed cancer (including respiratory, digestive, urogenital, nervous, endocrine, and soft tissue malignancies). Exclusion criteria: presence of non-cancer organic diseases, hematologic disorders, immunodeficiency (e.g., AIDS), or incomplete data.
Data collection: Blood biomarkers including complete blood count, biochemical tests (liver/kidney function, glucose, lipids), coagulation (PT, APTT, TT, fibrinogen), and tumor markers (e.g., CEA, CA19-9, AFP, CA125, etc.) along with clinical data (age, sex, height, weight, diagnosis) will be extracted from medical records.
Statistical analysis: A Mixture of Experts (MoE) architecture with deep residual networks, attention-based gating, and feature interaction (FM + deep neural networks) will be used. Multi-task learning, Focal Loss for class imbalance, and adaptive sample weighting will be applied. Model performance will be evaluated for sensitivity, specificity, and AUC.
Ethics: Approved by the Ethics Committee of Zhejiang Cancer Hospital (IRB-2025-1319[IIT]). Because this is a retrospective study using de-identified data, the committee approved a waiver of informed consent for patients without prior general consent, in accordance with Chinese regulations and the Declaration of Helsinki. Data will be encrypted and stored securely for 15 years after study completion.
Dissemination: Results will be published in peer-reviewed journals and presented at conferences.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Zhejiang Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pathologically confirmed cancer patients (for case group) OR individuals without cancer (for control group)
- Age between 18 and 80 years
- Complete clinical data and blood test results (complete blood count, biochemistry, coagulation panel, tumor markers) available
- No history of other organic diseases (excluding cancer)
Exclusion Criteria:
- Presence of organic diseases other than cancer (e.g., severe heart, liver, kidney disease)
- Hematologic disorders or immunodeficiency diseases (e.g., AIDS)
- Incomplete data or missing timeline records
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
All Participants
All enrolled individuals (cancer patients and non-cancer controls) with retrospective blood biomarker data.
|
This is an observational, retrospective study with no assigned interventions.
Data are collected from existing medical records, including routine blood biomarkers (complete blood count, biochemistry, coagulation panel, tumor markers).
No experimental drugs, devices, or procedures are administered.
Only de-identified historical data are used for model development.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area under the ROC curve (AUC)
Time Frame: At study completion, approximately December 2030
|
AUC of the MoE model for discriminating cancer from non-cancer controls.
|
At study completion, approximately December 2030
|
|
Sensitivity of the model
Time Frame: At study completion, approximately December 2030
|
True positive rate of the pan-cancer screening model.
|
At study completion, approximately December 2030
|
|
Specificity of the model
Time Frame: At study completion, approximately December 2030
|
True negative rate of the pan-cancer screening model.
|
At study completion, approximately December 2030
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Xiangdong Cheng, MD, PhD, Zhejiang Cancer Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-2025-1319[IIT]
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.